VRTX · News · 20261103N

Acquisition / Partnership / Divestiture

VERTEX PHARMACEUTICALS INC / MA · 2026-11-03 · Importance 40 · Surprise 42

Vertex acquired Crinetics Pharmaceuticals in September 2026, adding Palsonify to its commercial portfolio. The acquisition expanded Vertex’s presence into rare endocrine diseases and was cited as a contributor to the raised 2026 revenue guidance. Reports also cited acquisition-related costs and financing costs as factors weighing on earnings, but gave no transaction value or cost amounts.

Key facts